NCT06532344 2024-11-14An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerOno Pharmaceutical Co., Ltd.Phase 1 Active not recruiting32 enrolled